Detalles de la búsqueda
1.
Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
J Card Fail
; 30(1): 104-110, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072105
2.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Br J Clin Pharmacol
; 85(4): 762-770, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30618054
3.
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Br J Clin Pharmacol
; 84(7): 1486-1493, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29468715
4.
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
Pharmacol Res Perspect
; 12(2): e1184, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38445541
5.
Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
Eur J Heart Fail
; 25(9): 1696-1707, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37470101
6.
In vivo imaging of lipid storage and regression in diet-induced obesity during nutrition manipulation.
Am J Physiol Endocrinol Metab
; 303(11): E1287-95, 2012 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23032688
7.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Clin Drug Investig
; 41(10): 895-905, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34546534
8.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Clin Transl Sci
; 14(3): 812-819, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770730
9.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Clin Pharmacol Drug Dev
; 9(3): 411-421, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31793171
10.
Recombinant human prothrombin (MEDI8111) combined with fibrinogen dose-dependently improved survival time and reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
Blood Coagul Fibrinolysis
; 30(4): 140-148, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31090596
11.
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Clin Transl Sci
; 11(3): 330-338, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29517132
12.
Recombinant human prothrombin reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
Blood Coagul Fibrinolysis
; 28(3): 244-253, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428015
13.
Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies.
Scand J Trauma Resusc Emerg Med
; 25(1): 30, 2017 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292321
14.
Boosting the coagulation restores haemostasis in ticagrelor-treated mice.
Blood Coagul Fibrinolysis
; 27(8): 913-919, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26757017
15.
In vitro anti-platelet potency of ticagrelor in blood samples from infants and children.
Thromb Res
; 136(3): 620-4, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26210892
16.
INR variability in atrial fibrillation: a risk model for cerebrovascular events.
Eur J Intern Med
; 20(1): 63-9, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19237095
Resultados
1 -
16
de 16
1
Próxima >
>>